PLATINUM-RESISTANT OVARIAN CANCER
Clinical trials for PLATINUM-RESISTANT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental cancer pill tested in 23 patients, study halted early
Disease control TerminatedThis early-stage study tested an experimental oral drug called NKT3447 in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:28 UTC
-
Cancer drug study halted early: what happened?
Disease control TerminatedThis study tested an experimental drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the study…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New hope for tough ovarian cancer? trial tests targeted drug vs standard chemo
Disease control TerminatedThis study tested a new drug called luveltamab tazevibulin against standard chemotherapy in about 600 women whose ovarian cancer had stopped responding to platinum-based treatment. The drug targets a protein (FOLR1) found on many ovarian cancer cells. The trial was terminated ear…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2, PHASE3 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Ovarian cancer drug combo study halted early
Disease control TerminatedThis study tested a combination of two drugs, SON-1010 and atezolizumab, in people with advanced solid tumors and platinum-resistant ovarian cancer. The goal was to see if the combo was safe and could slow cancer growth. The study was terminated early, so results are limited. It …
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated May 19, 2026 11:48 UTC